Utama › Kanser Paru-paru Bukan Sel Kecil › Minnesota › Rochester
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Rochester, MN
37 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Rochester (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Mengambil pesertaFasa 1/2
- Mayo Clinic-Rochester /ID# 274512, Rochester
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 1/2
- Research Site, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1
- Exelixis Clinical Site #68, Rochester
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Mayo Clinic in Rochester, Rochester
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Mengambil pesertaFasa 3
- Mayo Clinic - Rochester ( Site 0073), Rochester
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Mengambil pesertaFasa 3
- Mayo Clinic - Rochester ( Site 0148), Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Mengambil pesertaKajian pemerhatian
- Mayo Clinic Rochester, Rochester
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- Mayo Clinic Rochester, Rochester
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- Mayo Clinic, Rochester
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Mayo Clinic, Rochester
Pan-tumor MRD Study
Mengambil pesertaKajian pemerhatian
- Mayo Clinic, Rochester
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Research Site, Rochester
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Mayo Clinic, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Mengambil pesertaKajian pemerhatian
- Mayo Clinic (Rochester), Rochester
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- Mayo Clinic, Rochester
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Mayo Rochester, Rochester
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Mengambil pesertaFasa 3
- Research Site, Rochester
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Mengambil pesertaFasa 1
- Mayo Clinic, Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Mengambil pesertaFasa 1
- Mayo Clinic - Rochester, Rochester
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Mengambil pesertaFasa 1
- Mayo Clinic, Rochester
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Mengambil pesertaFasa 1/2
- Mayo Clinic-Rochester, Rochester
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Mengambil pesertaSukarelawan sihat dialu-alukan
- Mayo Clinic in Rochester, Rochester
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Mengambil pesertaFasa 3
- Mayo Clinic in Rochester, Rochester
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Mengambil pesertaFasa 1/2
- Mayo Clinic Hospital - Rochester, MN, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Mengambil pesertaFasa 1
- Mayo Clinic Rochester, Rochester
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Mayo Clinic Cancer Center, Rochester
- Mayo Clinic, Rochester
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Mengambil pesertaFasa 3
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- Mayo Clinic Rochester, Rochester
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Mayo Clinic Comprehensive Cancer Center, Rochester
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Mengambil pesertaFasa 3
- Mayo Clinic, Rochester
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Mayo Clinic in Rochester, Rochester
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Mengambil pesertaFasa 1/2
- Mayo Clinic Cancer Center, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Mayo Clinic, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Mengambil pesertaKajian pemerhatian
- Mayo Clinic in Rochester, Rochester
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Mayo Clinic (Data Collection Only), Rochester
Insomnia in Patients With Metastatic Lung Cancer
Mengambil pesertaKajian pemerhatian
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- Mayo Clinic, Rochester
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Washington, DC55 kajian
Kajian lain di Rochester
- Kanser Payudara42 kajian
- Kanser Metastatik31 kajian
- Kanser (semua jenis)30 kajian
- Kanser Ovari29 kajian
- Kanser Kolorektal29 kajian
- Mieloma Pelbagai24 kajian
- Kegagalan Jantung22 kajian
- Kanser Prostat22 kajian
- Kanser Pankreas22 kajian
- Kanser Endometrium20 kajian
- Kanser Paru-paru20 kajian
- Leukemia Limfositik Kronik18 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.